Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies

Cell Reports

Volumn 15, Issue 2, 2016, Pages 264-273

  Rojas, Juan J ^a   Sampath, Padma ^a   Bonilla, Braulio ^a   Ashley, Alexandra ^a   Hou, Weizhou ^a   Byrd, Daniel ^a   Thorne, Steve H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; THYMIDINE KINASE; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DEGLYCOSYLATION; DRUG EFFICACY; DRUG SAFETY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; KIDNEY CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENE; TUMOR VOLUME; TUMOR XENOGRAFT; VACCINIA SURFACE DEGLYCOSYLATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; GLYCOSYLATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NECROSIS; NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VACCINIA VIRUS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GLYCOSYLATION; IMMUNOTHERAPY; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NECROSIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; THYMIDINE KINASE; TOLL-LIKE RECEPTOR 2; VACCINIA VIRUS;

EID: 84962073735     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.017     Document Type: Article

References (30)

1. Andtbacka R.H.I., Collichio F.A., Amatruda T., Senzer N.N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Doleman S., Ye Y., et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. 2013, 31:LBA9008.
2. Chakrabarti S., Sisler J.R., Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23:1094-1097.
3. Chen H., Sampath P., Hou W., Thorne S.H. Regulating cytokine function enhances safety and activity of genetic cancer therapies. Mol. Ther. 2013, 21:167-174.
4. Essajee S., Kaufman H.L. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 2004, 4:575-588.
5. Ganly I., Kirn D., Eckhardt G., Rodriguez G.I., Soutar D.S., Otto R., Robertson A.G., Park O., Gulley M.L., Heise C., et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000, 6:798-806.
6. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002, 8:503-507.
7. Heo J., Reid T., Ruo L., Breitbach C.J., Rose S., Bloomston M., Cho M., Lim H.Y., Chung H.C., Kim C.W., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 2013, 19:329-336.
8. Ilkow C.S., Marguerie M., Batenchuk C., Mayer J., Ben Neriah D., Cousineau S., Falls T., Jennings V.A., Boileau M., Bellamy D., et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med. 2015, 21:530-536.
9. June C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007, 117:1466-1476.
10. Kaiser W.J., Sridharan H., Huang C., Mandal P., Upton J.W., Gough P.J., Sehon C.A., Marquis R.W., Bertin J., Mocarski E.S. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 2013, 288:31268-31279.
11. Khuri F., Nemunaitis J., Ganly I., Gore M., MacDougal M., Tannock I., Kaye S., Hong W., Kirn D. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat. Med. 2000, 6:879-885.
12. Kirn D., Ganley I., Nemunaitis J., AL E. A phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck cancer. Cancer Gene Ther. 1997, 4.
13. Kirn D., Hermiston T., McCormick F. ONYX-015: clinical data are encouraging. Nat. Med. 1998, 4:1341-1342.
14. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
15. O'Gorman W.E., Sampath P., Simonds E.F., Sikorski R., O'Malley M., Krutzik P.O., Chen H., Panchanathan V., Chaudhri G., Karupiah G., et al. Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses. Cell Host Microbe 2010, 8:174-185.
16. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., Stoute J.A., Magill A., Krzych U., Farley L., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 1998, 177:1664-1673.
17. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011, 29:330-336.
18. Park B.H., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., Oh S.Y., Han S.Y., Yoon J.H., Hong S.H., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9:533-542.
19. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
20. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat. Rev. Clin. Oncol. 2011, 8:577-585.
21. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
22. Sampath P., Li J., Hou W., Chen H., Bartlett D.L., Thorne S.H. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol. Ther. 2013, 21:620-628.
23. Schmidt C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat. Biotechnol. 2011, 29:295-296.
24. Seya T., Matsumoto M. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol. Immunother. 2009, 58:1175-1184.
25. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505.
26. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
27. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., Schlesinger S.J., Colonna M., Steinman R.M. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. USA 2008, 105:2574-2579.
28. Wang Z., Choi M.K., Ban T., Yanai H., Negishi H., Lu Y., Tamura T., Takaoka A., Nishikura K., Taniguchi T. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc. Natl. Acad. Sci. USA 2008, 105:5477-5482.
29. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., Schmitt E., Schild H., Radsak M.P. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108:544-550.
30. Zhu X., Fallert-Junecko B.A., Fujita M., Ueda R., Kohanbash G., Kastenhuber E.R., McDonald H.A., Liu Y., Kalinski P., Reinhart T.A., et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol. Immunother. 2010, 59:1401-1409.